On January 14, 2025, the Company reported positive outcomes observed from the interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryteTM treatment for up to 12 ...

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET. Company Participants. Andrew Funderburk - Senior Vice President, Investor Re ...

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 ...

The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient ...

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...